Laird Norton Wetherby Wealth Management LLC cut its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 31.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 26,447 shares of the pharmaceutical company's stock after selling 11,992 shares during the period. Laird Norton Wetherby Wealth Management LLC's holdings in GSK were worth $894,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. FMR LLC lifted its position in shares of GSK by 82.1% during the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock valued at $1,786,475,000 after acquiring an additional 23,814,104 shares during the last quarter. Primecap Management Co. CA lifted its holdings in shares of GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock valued at $854,349,000 after purchasing an additional 10,407,905 shares during the last quarter. Bridgewater Associates LP increased its stake in GSK by 132.7% in the 4th quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company's stock worth $76,017,000 after purchasing an additional 1,281,855 shares in the last quarter. Schonfeld Strategic Advisors LLC increased its stake in GSK by 68.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,237,034 shares of the pharmaceutical company's stock worth $75,656,000 after purchasing an additional 907,068 shares in the last quarter. Finally, Kahn Brothers Group Inc. acquired a new stake in GSK during the 4th quarter worth about $29,921,000. 15.74% of the stock is currently owned by institutional investors.
GSK Price Performance
NYSE GSK opened at $36.25 on Thursday. The company has a 50 day moving average price of $37.48 and a two-hundred day moving average price of $35.98. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.93. The stock has a market capitalization of $74.79 billion, a PE ratio of 22.80, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.
GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.05. The business had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. GSK's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.43 EPS. As a group, equities analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.
GSK Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $0.4216 per share. This is a positive change from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.65%. GSK's dividend payout ratio is currently 86.60%.
Wall Street Analysts Forecast Growth
GSK has been the topic of several analyst reports. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. BNP Paribas initiated coverage on shares of GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price on the stock. Morgan Stanley began coverage on GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, GSK has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.
Read Our Latest Stock Report on GSK
GSK Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Further Reading
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
